It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NUVL’s FA Score shows that 0 FA rating(s) are green whileROIV’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NUVL’s TA Score shows that 6 TA indicator(s) are bullish while ROIV’s TA Score has 4 bullish TA indicator(s).
NUVL (@Biotechnology) experienced а +0.68% price change this week, while ROIV (@Biotechnology) price change was -2.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.
NUVL is expected to report earnings on Mar 04, 2026.
ROIV is expected to report earnings on Feb 06, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NUVL | ROIV | NUVL / ROIV | |
| Capitalization | 8.32B | 15.3B | 54% |
| EBITDA | -398.38M | -1.14B | 35% |
| Gain YTD | 6.541 | 1.244 | 526% |
| P/E Ratio | N/A | 1.97 | - |
| Revenue | 0 | 20.3M | - |
| Total Cash | 943M | 4.39B | 22% |
| Total Debt | N/A | 98.8M | - |
| NUVL | ROIV | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 64% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 70% |
| Advances ODDS (%) | 1 day ago 82% | 1 day ago 74% |
| Declines ODDS (%) | 10 days ago 77% | 8 days ago 69% |
| BollingerBands ODDS (%) | 1 day ago 81% | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| 1 Day | |||
|---|---|---|---|
| FOREX / NAME | Price $ | Chg $ | Chg % |
| AUDCAD | 0.95 | N/A | N/A |
| Australian Dollar - Canadian Dollar | |||
| GBPNZD | 2.27 | N/A | N/A |
| United Kingdom Pound - New Zealand Dollar | |||
| NZDAUD | 0.86 | N/A | N/A |
| New Zealand Dollar - Australian Dollar | |||
| CHFGBP | 0.94 | N/A | N/A |
| Switzerland Franc - United Kingdom Pound | |||
| QDTE | 30.52 | -0.45 | -1.45% |
| Roundhill Innovt-100 0DTE CovCllStratETF | |||
A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.
| Ticker / NAME | Correlation To NUVL | 1D Price Change % | ||
|---|---|---|---|---|
| NUVL | 100% | +2.12% | ||
| XNCR - NUVL | 61% Loosely correlated | -0.99% | ||
| CGON - NUVL | 60% Loosely correlated | -3.28% | ||
| RVMD - NUVL | 59% Loosely correlated | -1.22% | ||
| IDYA - NUVL | 58% Loosely correlated | +0.50% | ||
| XENE - NUVL | 58% Loosely correlated | +1.62% | ||
More | ||||
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | +0.14% | ||
| IMVT - ROIV | 59% Loosely correlated | -1.07% | ||
| NUVL - ROIV | 50% Loosely correlated | +2.12% | ||
| KYMR - ROIV | 49% Loosely correlated | +2.12% | ||
| RVMD - ROIV | 48% Loosely correlated | -1.22% | ||
| CRNX - ROIV | 48% Loosely correlated | +1.24% | ||
More | ||||